Sponsored Symposia

Personalising Type 2 asthma treatment with Dupilumab – evidence and clinical experience

Session Date: Saturday, 1 May 2021
Session Time: 0700-0815

A/Prof David Langton OAM, Director, Thoracic And Sleep Medicine, Peninsula Health
Dr Michael E Wechsler, Professor of Medicine, National Jewish Health, Denver, CO, USA and Director, NJH Cohen Family Asthma Institute in the Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA

Following the PBS listing of Dupixent for severe asthma, Sanofi would like to align with requests from HCPs about Dupixent’s clinical evidence and experience gained by HCPs in previously launched international markets as well as from their peers locally. Symposium aims to provide practical guidance on where Dupixent fits into severe asthma management and what factors influence the choice of biologic therapy to achieve best possible outcomes for asthma patients. Dupixent is a human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines that play a central role in type 2 inflammation that underlies specific types of asthma as well as several other allergic diseases. Dupixent is indicated in Australia for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy, not indicated for episodic use. Dupixent is also indicated for add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO). It is indicated as maintenance therapy for oral corticosteroid dependent asthma.

Functional Lung Imaging: Translational Medicine and Clinical Applications


Date: Saturday, 1 May
Time: 1320-1350

Professor Naresh M. Punjabi MD, PhD, Chief of Pulmonary Critical Care & Sleep Medicine, University of Miami

Understanding of the determinants of ventilation defects and ventilation heterogeneity may lead to more efficacious treatments for acute and chronic lung diseases, and can provide an additional approach for monitoring treatments to improve long-term outcomes for patients. This symposium addresses state-of-the-art, non-invasive lung imaging used to determine functional deficits in regional lung motion and airflow.

From lab to Lizzy – the Australian story behind eosinophils


Date: Saturday 1 May
Time: 1850-2005 

Dr Li Ping Chung, Fiona Stanley Hospital, Western Australia
Professor Paul Foster, The University of Newcastle, Hunter Medical Research Institute
Professor Peter Gibson, The University of Newcastle, Hunter Medical Research Institute
Professor Vanessa McDonald, The University of Newcastle, Hunter Medical Research Institute

Chair: Dr Li Ping Chung, Fiona Stanley Hospital, Western Australia

We invite you to take a step back in time and trace the journey of the eosinophils and IL-5 from discovery to patient. In this meeting we will hear from Australian investigators and researchers who have led the discovery, development and real world application of targeted therapies such as mepolizumab (Nucala). Lizzy*, a patient from the Australian Mepolizumab Registry will also join us to share her experience of living with severe asthma.

(*Lizzy is a fictional name used for the purposes of the synopsis, we are planning to have a real patient as part of the symposium).

Transformative Strategies for the Management of Respiratory Illness 


Date: Sunday, 2 May
Time: 0700-0815

Professor Daiana Stolz: Associate Professor for Respiratory Medicine and Research Group Head, University Hospital Basel
Dr Emily Stone: Consultant Respiratory Physician and Acting Head of Thoracic Medicine, St Vincent’s Hospital Sydney.

Lung and respiratory diseases represent a significant health burden in Australia, with lung cancer and COPD reported as the 4th and 5th leading causes of death in 2018, respectively1. This symposium presents opportunities to improve outcomes for patients with topics covering Earlier Intervention in COPD and Lung Cancer Screening in Australia

The most recent GOLD strategy updates recognise the importance of assessing the impact of symptoms and future risk for an individual patient in deciding appropriate and individualised treatments, which better reflect the patient’s own goals and needs. The long term goals of COPD management should be focussed on reducing the overall burden to the patient; including their risk of serious exacerbations, disease progression and COPD-related death2.

Lung cancer continues to be a significant burden in Australia and the leading cause of cancer-related death. With most lung cancer still diagnosed at an advanced stage, little progress has been made with improving survival rates. Diagnosing lung cancer in earlier stages of disease will meaningfully improve outcomes for lung cancer patients. This is supported by international evidence showing that lung cancer screening programs can increase early stage identification and overall survival3. Based on this evidence, Cancer Australia has recently published a report from the Lung Cancer Screening enquiry, recommending the adoption of a Lung Cancer Screening program in Australia3. The aim of a screening program would be to identify high risk patients for referral and assessment.


Targeting peripheral airways dysfunction in the management of COPD


Date: Sunday, 2 May
Time: 1320-1350

Prof Bruce Thompson: Respiratory Physiologist, Dean of Health Science at Swinburne University of Technology, Melbourne
Dr John Blakey: Consultant in Respiratory Medicine, Sir Charles Gairdner Hospital, Perth

Chair: Prof Bruce Thompson

Despite the prevalence of COPD being as high as 1 in 7 Australians over the age of 40 years and the second leading cause of preventable hospital admissions in Australia1, the diagnosis and management of this obstructive lung condition remain suboptimal.

COPD is a disease of the peripheral or “small airways” and evidence has shown that small airways inflammation is present even in mild disease. Recent research has seen a resurgence in physiological and imaging techniques that are able to reliably assess and characterise peripheral airways in COPD patients. This has led to an interest in studying the effect of small particle sized inhaled therapies that are able to reach and potentially treat the peripheral airways.

This session will provide an update to participants on the evidence supporting treatment of COPD with a new extrafine fixed combination ICS/LABA/LAMA pMDI and its place in therapy in the Australian context. In addition, this update aims to educate Australian healthcare professionals on key changes to local and international guidelines to guide their management of their COPD patients.

  1. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald V, Smith B, Zwar N, Dabscheck E. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2020. Version 2.61, February 2020.